Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 1, 2012Hematology

Breakthroughs in myeloproliferative neoplasms

View Full Paper
Ask AI
Bookmark
Share

Authors

FSFábio Pires de Souza SantosHospital Israelita Albert Einstein
Srđan Verstovšek
Srđan VerstovšekUppsala University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Santos et al. (2012) studied this question.

synapsesocial.com/papers/6a1fdfc4dfff2a7ea2430b53https://doi.org/10.1179/102453312x13336169155574
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis2009 · 193 citations
  2. 2Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis2010 · 1,172 citations
  3. 3Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis2011 · 149 citations
  4. 4Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia-myelofibrosis (PET-MF).2011 · 31 citations
  5. 5Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis2011 · 399 citations